乙型肝炎抗原阳性的慢性乙型肝炎患者的粪便菌群移植：一

StephenW

Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study

    Ashish Chauhan, Ramesh Kumar, Sanchit Sharma, Mousumi Mahanta, Sudheer K. Vayuuru, Baibaswata Nayak, Sonu Kumar & Shalimar

Digestive Diseases and Sciences volume 66, pages873–880(2021)Cite this article

    307 Accesses

    3 Citations

    3 Altmetric

    Metrics details

Abstract
Background

Intestinal flora plays a critical role in immunity against hepatitis B virus (HBV). Fecal Microbiota Transplantation (FMT) may be a potential immunomodulatory therapy in patients with chronic hepatitis B (CHB).
Aim

We aimed to study role of FMT in hepatitis B e antigen (HBeAg)-positive CHB patients in terms of its effect on HBeAg, HBsAg, and HBV DNA.
Methods

HBeAg-positive patients despite being on antiviral treatment for > 1 year were given six cycles of FMT via gastroscope (nasoduodenal route) at 4 weekly intervals along with antiviral therapy. Twelve out of 14 included patients in FMT arm completed six cycles. Another 15 HBeAg-positive patients who were on oral antivirals for > 1 year were taken as control—antiviral therapy (AVT) arm. Per-protocol analysis was done.
Results

The median (interquartile range) age in the FMT and AVT arm were 29 (25–35) and 29(24–38), respectively (P = 0.794). The median (interquartile range) duration of AVT prior to inclusion in the study was 80 (52–104) and 76 (52–114) months in FMT and AVT arm, respectively (P = 0.884). In the FMT arm, 16.7% (2/12) patients had HBeAg clearance in comparison to none in the AVT arm (P = 0.188). None of the patients in either arm had HBsAg loss. The FMT was tolerated well, 42.8% (6/14) patients reported one or more minor adverse events.
Conclusions

In this non-randomized pilot study, FMT appears to be safe and potentially effective in terms of viral suppression and HBeAg clearance in patients with HBeAg-positive CHB. Further randomized controlled trials are needed in order to obtain robust conclusions.

StephenW

乙型肝炎抗原阳性的慢性乙型肝炎患者的粪便菌群移植：一项初步研究

    Ashish Chauhan，Ramesh Kumar，Sanchit Sharma，Mousu​​mi Mahanta，Sudheer K.Vayuuru，Baibaswata Nayak，Sonu Kumar和Shalimar

消化系统疾病，第66卷，第873–880页（2021），引用本文

    307次访问

    3引文

    3高度

    指标详细信息

抽象的
背景

肠道菌群在抵抗乙型肝炎病毒（HBV）的免疫中起着至关重要的作用。粪便微生物菌群移植（FMT）可能是慢性乙型肝炎（CHB）患者的一种潜在的免疫调节疗法。
目的

我们旨在研究FMT在乙型肝炎e抗原（HBeAg）阳性CHB患者中的作用，根据其对HBeAg，HBsAg和HBV DNA的影响。
方法

尽管接受抗病毒治疗超过1年的HBeAg阳性患者通过胃镜（鼻十二指肠途径）每隔4周一次进行了六个周期的FMT联合抗病毒治疗。 FMT组的14名患者中有12名完成了6个周期。接受口服抗病毒药物治疗≥1年的15例HBeAg阳性患者被作为对照组-抗病毒治疗（AVT）组。按协议进行分析。
结果

FMT和AVT组的中位年龄（四分位间距）分别为29岁（25-35岁）和29岁（24-38岁）（P = 0.794）。在纳入研究之前，FMT和AVT组中AVT的中位（四分位间距）持续时间分别为80（52–104）和76（52–114）月（P = 0.884）。在FMT组中，有16.7％（2/12）的患者具有HBeAg清除率，而在AVT组中则没有（P = 0.188）。两组的患者均无HBsAg丢失。 FMT的耐受性良好，有42.8％（6/14）的患者报告了一种或多种轻微不良事件。
结论

在这项非随机的先导研究中，就HBeAg阳性CHB患者的病毒抑制和HBeAg清除而言，FMT似乎是安全且潜在有效的。为了获得可靠的结论，还需要进一步的随机对照试验。